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CHAPTER iO
Interplay between medicine and
biochemistrY
H. COENRAAD HEMKER
(Jniversity of Limburg, Biomedical Centre, Maastricht (The Netherlands)
Medical science, not surprisingly, flowers at the interface of medicine and sci-
ence. Its bloom thus resulti trom ine confrontation of two different cultures. Al-
though it is good custom to emphasize the warm relations between the two, it is
of nJ use to dissimulate the distance that separates doctors and scientists' Indeed
the gap is large enough to use the expression 
'two cultures' not exclusively as a
aesciiption oithe situation between the sciences and the humanities' There is suf-
ficient reason to maintain that it applies as well to the sciences confronting med-
icine. A good doctor is primarily interested in the well-being of his patients and
uses scientific insight oniy ut one of the tools of his trade. It is rare to find him
develop an expert knowledge in a branch of natural science. on the other hand a
scienti it opts fbr insight, no-matter how delighted he may be tofnd his results of
use in the diagnosis and treatment of the sick. The fundamental difference in at-
titude between the two makes that the exploration of the interface between sci-
ence and medicine often is diff icult. In fact every symposium or congress rn one
field or another of human pathobiology teaches us that although doctors and sci-
entists meet frequently, their views only amalgamate with difficulty'
There is good ."uron to stress this point if one is to discuss the interplay be-
tween medii ine and science in the field of blood coagulation. There is hardly an-
other subject of study in human biology where the clinics have remained the most
importani source of information for so long. Whereas e.g. endocrinology or im-
munology had their science components developed already during the first half of
this ceniury, haemostasi. ,.reurih remained the playground of the doctors. There
probably are multiple reasons for this, such as the rareness of congenital bleeding
Oirord.ir, that are the most natural first object of study or the complexity of the
problem that presents itself already after the first few experiments' to defy any
simplifying hypothesis etc. I would not maintain that blood coagulation per se is
.noi. **ltliiteO rhan immunology or endocrinology or any other subject of hu-
man path;physiology. It only presents its complexity right at th-e beginning of the
most^simpli expe.iments. This makes people tend to shy away from an attempt at
a formal icientific approach. Even in 1962, when I planned to enter the field, my
colleague biochemisti were shocked to see that I would consider that kettle of f ish
worth; of my attention. My medical colleagues did not share these objections al-
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though they failed to see why I should stop medical practice. while plaving around
with tubes. At that t ime the lab carrying most weight in the field of blood coag-
ulation was that in Oxford where R.G. Macfarlane, M.D. and clinical pathologist.
together with Rosemary Biggs, Ph.D. and originally a botanist. formed a nucleus
around which many medical doctors and several scientists gathered and formed a
group that was responsible for many fine contributions. Yet, even there. the ap-
plication of modern biochemical techniques was less fruitful than the typical co-
agulation approach, that in essence exists of measuring clotting times in endless
permutations and combinations of mixtures. 'After all' Rosemary Biggs used to
say'After all i t is more l ike cooking than like anything else'. In Detroit, Walter
Seegers, M.D. and professor of physiology, devoted his l i fe to attempts at pun-
fying prothrombin and other clotting factors. Rereading the articles from this group
one is struck by the tremendot' i amount of work, by the many observations done
that can only be explained in the l ight of our newest knowledge (cf. Ch. 98). Also
by the fact that the results did not even allow the construction of a refutable set
of hypotheses.
It must be said that, with all their cooking and curing the doctors had done a
good job. By 1960 most of the coagulation 'factors' had been defined as functions
lacking in haemophilic disorders. The role of blood platelets had been discerned
and the pathology of thrombosis had been described in great detail. A good start
had been made with anticoagulant treatment and with the treatment of haemo-
philia by the use of plasma fractions.
Mentioning the pathology of thrombosis automatically evokes Virchow and the
scientists of the 19th and early 20th centuries. What about the interactions be-
tween medicine and science in those days? Buchanan (M.D.) was the first to re-
port (1836) that catalytic amounts of clotted blood could coagulate a fibrinogen
iolution. His fibrinogen solution was prepared involuntarily in the scrotum of pa-
tients suffering from a hydrocele. These experiments can - a posteriori - hardly
be thought to be conclusive but they did introduce the concept of coagulation by
enzymatic conversion that we now know to be correct. In the second half of the
19th century this concept was heavily opposed a.o. by Alexander Schmidt who fa-
voured the idea that fibrin arises from a stoichiometric interaction between blood
proteins. Others, like e.g. Hammersten sustained Buchanan's view, often with ex-
perimental evidence that up to this moment seems convincing. Nevertheless, even
with all the old literature on one's desk it is hard to find out what was really meant.
Some workers like Hammersten describe experiments with meticulous precision;
others, like Schrnidt prefer general considerations but in any case our observation
of their results is tinged with our present knowledge. The controversy that domi-
nates the blood coagulation literature in the latter half of the last century is that
between those who se. fibrin as the product of the catalytic action of thrombin on
fibrinogen and those who think fibrin to arise from the stoichiometric action of fi-
brinogen and a second substance. The gist of this controversy seems to be that at
that time no distinction could be made between the functions of thrombin and that
of thromboplastin. In trying to repeat the old experiments it often up to this day
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cannot be made clear in what modern terms they should be explained. The same
confusion repeats itself about half a century later when the two functions of
thromboplastin are recognised: tissue thromboplastin as we know it and 
'blood-
thromboplastin' now knlwn to be prothrombinase. With combinations of crude
blood fractions and thromboplastin-iontaining preparations (cells, serum etc') ob-
servations can be made that indeed suggest stoichiometric interactions but others
suggestive of enzymatic interaction are possible as well. Join to this that nomen-
cla"t*ure in those duy, *u, confused to thi degree of complete incomprehensibility
and that communications often hardly crossed the national borders then one will
be hardly surprised by the fact that a communis opinio was not reached until around
the turn of the century. After 1876 Schmidt began to accept reluctantly that
thrombin might play a role in the generation of fibrin and he postulated that it cir-
culates in the blood in an inactive precursor state'
The type of argument used in th; 19th century discussions switched from med-
ical observations to chemical experiments and back with an astonishing ease, es-
pecially where, as in the .ur" of Schmidt, the borderline between discussion and
specutation faded. Schmidt was a medical doctor and professor of physiology'
Aammersten was a chemist. It would in my opinion be unjustified to attribute the
difference in style between these two scientist to a difference in discipline' I would
rather see it as a question of temper. Temper anyhow spices these discussions, even
to a degree that we nowadays would think unpalatable. From the literature of the
19th ce*ntury the impression remains that doctors and chemists did not work in dif-
ferent worlds but rather cooperated and penetrated each others fields freely' Out-
side coagulation one might t-hink of the chemist Pasteur who cured rabies or, con-
versely, 
-of 
the first geneiation of biochemists who were almost exclusively medical
doctois. perhaps inlhose times the new ground to cover was so enormous that one
did not bother about subdivisions. Perhaps, on the other hand, we tend to stick
too much to our disciplines these days.
In the field of blood coagulation there is a very interesting personality that up
to this moment did hardly [et ttre attention he deserves: Cornelis A' Pekelharing
(Fig. 1), a medical doctor who became professor of general pathology at the uni-
*,"r! ity'of Utrecht, The Netherlands, in 1881. In 1894 he described experiments
that up to this day can be easily repeated and that demonstrate the existence of
prothrombin. By repeated precipitations with NaCl and/or MgSOa he obtained two
fractions from normal plasma,-neither of which clotted upon addition of CaCl2
and/or t issue thrombopiastin. One of the preparations, however' after these ad-
ditions acquired the capacity to make the other one clot. Pekelharing drew the
correct conclusion: R pioeniyme, prothrombin, is converted, under the influence
of tissue thromboplastin and caclr, into an enzyme, thrombin that can make fi-
brinogen clot.
ToLy knowledge this does not only mark the discovery of prothrombin but also
is the first demonstration of a proenzyme-enzyme conversion' It thus shows that
the work of an M.D. on a medical problem often can yield results that are of sem-
inal importance to biological sciences, to biochemistry in this case' It thus is a per-
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Fig. 1. Cornelis A' Pekelharing (1848-f922)'
f ec texamp leo foneo f thema in fea tu reso f the in te rac t i ono fmed ic ineandchem-
ist ry :medicalproblemsareatreasuretrovefor thebiochemistwhotakesthepain
to understand them;;U. i;iting *ittr a clinician 
and trying to understand his
problemsmaybemoredi f f icu l t thanrunninganul t racentr i fugeor interpret ingki -
netic data but it mayi"-"ill"" as fruitful]The traffic between 
biochemists and
medical doctors is oftJri i"-p"r"o by the failure 
of either one to try and under-
s tand theo the r , s l anguage .Nowth i scan indeedbed i f f i cu l t . I havehad thep leas -
ure to work as u .rintui assistant in the paediatric 
clinics of a pioneer of blood
coagulation r"r"ur.n,-proi- s. uun creveid. The 
astonishing ease with which he
couldsuggest themost .ompt icateobiochemical researchonthespurofapat lent
seen (,After tnis uu.uiion Je will attack *n witt"utand's disease') 
was only ri-
valled by the astonisii'rif urr.*"., that the scientists 
did indeed find under such
guidance. I remind you of the discovery of platelet factor 3 (Paulssen) or the pu-
nlcation of factor VIII (van Mourik). On the other hand scientists tend to impose
their way of thinking on their medical colleagues, more often focussing on prob-
lems that are l ikely to be solved than on those that wil l help to gain insight in path-
ophysiological mechanisms. Yet, up to this day, the l iaisons and cross-ferti l isations
between scientists and practit ioners remain many and varied. We see Prof. Mag-
nusson, M.D., solve the primary structure of prothrombin and Prof. Duckert, Ph.
D., solve many problems directly related to patient care. We see the medical doc-
tors continuously improve on the quality of their clinical trials under the contin-
uous criticism of the statisticians and we continue to find patients that help us pose
problems of fundamental interest and solve them. It is only relatively recently that
the Fletcher and Fleaujac deficiencies led to the discovery of the details of contact
activation, that a study of the membrane proteins in congenital thrombopathies gave
important clues to the receptor functions in platelets or that the problems of the
control of oral anticoagulation inspired the experiments that led to the discovery
of carboxyglutamic acid and the mechanism of action of vitamin K.
A 'more than life size' example plays just at this moment (October 1984) in our
laboratory while Mrs. Scott is visit ing us. Mrs. Scott is an American lady who was
treated by Dr. Weiss in New York for a mild thrombopathy that he could define
to be a lack of platelet procoagulant activity. Later the group of Dr. Majerus in
St. Louis also did experiments with her platelets and they concluded that a mem-
brane protein receptor for the formation of prothrombinase was lacking. On the
basis of quite different experiments our group arrived at the conclusion that it is
rather the transbilayer l ipid movement in platelets that causes platelet procoagu-
lant activity. It makes phosphatidyl serine available at the outside of the mem-
brane, which is crucial to the procoagulant activity of any phospholipid prepara-
tion. Now indeed if the platelets of Mrs. Scott can be shown to lack a protein
receptor the 'American' view must be deemed right. On the other hand, if Mrs.
Scott's platelets do not show phospholipid flip-flop, our concept of PF 3 is the more
likely one. So at this moment we are determining whether only prothrombinase-
forming capacity is lacking in her platelets or whether the capacity to support the
formation of the factor X-converting enzyme is lacking as well. If this is the case,
either the receptor is aspecific or two receptors are lacking at the same time' We
will also see whether or not phosphatidyl serine wil l show up at the outside of her
triggered platelets. In this way we hope to settle a difference in opinion in a way
that wil l convince our American colleagues (cf. Rosing et al. (1985) Blood 65,
1ss7-1s61).
This case is a perfect modern example of the continuous need, also in modern
biochemistry, of ' the experiment of nature' that is to be found in the clinics. Also
of the continuous need for biochemists alert for rare cases presented by clinicians
and of the need for continuous attention from the side of the doctors, in order to
find those cases that may help solve scientif ic problems. Alas it must be said that
only a small part of the doctors burdened by an everyday practice have the talent
and/or interest to pay attention to this part of medical science. And also that those
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who do. wil l often not f ind a scientist competent and wilt ing 
to l isten to thetr stor\
and grasp its possible rn"uning' The fact thit such contacts 
are rare makes one think
ttrat"mucn valuable material slips constantl '
This is readily i l lustrated by the fact that
genital f ibrinogen abnormality seems to c
iation tabs are to be found' One wonders
ical doctors responsible for the research.l
sti l l  is often seen nowadays is, in my opln
so formidable that one of them - usually
b joins in an existing dialogue between re-
ion as 'case hunters' may be of great use' I
linics and basic science up to this day is of
paramount importanceinhaemostastsandthrombosisresearch.Wemustconfess
that thedi f f icu l t iest t ,u tu, i , " inestabl ish ingthenecessary l inksareof tenofanor-
ganisat ionalunOp.yt f to f 'og i tut"utut t 'Recognis ingth ismaybeaf i rs ts teptoaso-
t"ti:ir"* 
of the special subject of this articre it is hardly usefur to publish 
a list of
references. To the ,""d;; interested in the history 
of blood^coagulation research
anex tens i veb ib l i og raphyo f the l i t e ra tu reup toa round lg00 i sava i l ab leupon re -
quest.
